Drug Profile
Lapatinib - Novartis
Alternative Names: 572016; Cipatinib; GSK-572016; GW 572016; GW-2016; GW-572016F; Lapatinib - GSK; Lapatinib ditosilate; Lapatinib ditosylate; Tykerb; TyverbLatest Information Update: 06 Jan 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; GSK; National Taiwan University Hospital; Novartis; West German Study Group
- Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III Brain metastases
- Phase II Colorectal cancer; Non-small cell lung cancer
- No development reported Bladder cancer
- Discontinued Gastric cancer; Head and neck cancer; Prostate cancer
Most Recent Events
- 04 Jan 2024 No development reported - Phase-II/III for Bladder cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)
- 04 Jan 2024 No development reported - Phase-III clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy) in United Kingdom, Taiwan, Ukraine, Sweden, Spain, South Korea, Russia, Romania, Peru, Pakistan, Norway, Norway, Lithuania, India, Hungary, Hong Kong, Greece, Germany, France, Czech Republic, Italy (PO)
- 02 Jun 2023 Updated efficacy data from the phase III Neo ALTTO trial in Breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)